Becker's Healthcare February 19, 2024
While a majority of corporate health insurance plans cover glucagon-like peptide-1 receptor agonist drugs for diabetes, less than a third said they cover the class of drugs for weight loss. However, experts say it’s only a matter of time before more employers move to cover obesity treatments, CNBC reported Feb. 16.
The report cited an October survey of 205 companies in which 76% of respondents said they offered GLP-1 coverage for diabetes, while just 27% said they provided coverage for weight loss. Meanwhile, 13% indicated they were considering extending coverage to include GLP-1s approved for obesity, including Wegovy and Zepbound.
Despite hesitancy stemming from the drugs’ high price tags and questions over long-term benefits costs, many experts still anticipate...
Today's Sponsors
Today's Sponsor